281 related articles for article (PubMed ID: 15541815)
21. Aberrant methylation of Fragile Histidine Triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma.
Lee EJ; Lee BB; Kim JW; Shim YM; Hoseok I; Han J; Cho EY; Park J; Kim DH
Eur J Cancer; 2006 May; 42(7):972-80. PubMed ID: 16564166
[TBL] [Abstract][Full Text] [Related]
22. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
[TBL] [Abstract][Full Text] [Related]
23. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
24. Loss of FHIT function in lung cancer and preinvasive bronchial lesions.
Sozzi G; Pastorino U; Moiraghi L; Tagliabue E; Pezzella F; Ghirelli C; Tornielli S; Sard L; Huebner K; Pierotti MA; Croce CM; Pilotti S
Cancer Res; 1998 Nov; 58(22):5032-7. PubMed ID: 9823304
[TBL] [Abstract][Full Text] [Related]
25. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
26. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma.
Tzao C; Sun GH; Tung HJ; Hsu HS; Hsu WH; Wang YC; Cheng YL; Lee SC
Ann Thorac Surg; 2006 Aug; 82(2):396-401; discussion 401. PubMed ID: 16863736
[TBL] [Abstract][Full Text] [Related]
27. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.
Zhang Y; Wang R; Song H; Huang G; Yi J; Zheng Y; Wang J; Chen L
Cancer Lett; 2011 Apr; 303(1):21-8. PubMed ID: 21255913
[TBL] [Abstract][Full Text] [Related]
28. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers.
Hanabata T; Tsukuda K; Toyooka S; Yano M; Aoe M; Nagahiro I; Sano Y; Date H; Shimizu N
Oncol Rep; 2004 Jul; 12(1):177-80. PubMed ID: 15201980
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation markers and early recurrence in stage I lung cancer.
Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG
N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602
[TBL] [Abstract][Full Text] [Related]
31. Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer.
Wang J; Walsh G; Liu DD; Lee JJ; Mao L
Cancer Res; 2006 Sep; 66(17):8361-6. PubMed ID: 16951144
[TBL] [Abstract][Full Text] [Related]
32. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
33. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma.
Takada S; Morita K; Hayashi K; Matsushima T; Sawamura M; Murakami H; Nojima Y
Eur J Haematol; 2005 Dec; 75(6):505-10. PubMed ID: 16313263
[TBL] [Abstract][Full Text] [Related]
34. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan.
Wang J; Cheng YW; Wu DW; Chen JT; Chen CY; Chou MC; Lee H
Cancer Lett; 2006 Apr; 235(1):18-25. PubMed ID: 15935551
[TBL] [Abstract][Full Text] [Related]
35. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.
Kim JS; Han J; Shim YM; Park J; Kim DH
Cancer; 2005 Nov; 104(9):1825-33. PubMed ID: 16177988
[TBL] [Abstract][Full Text] [Related]
36. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer.
Choi CH; Lee KM; Choi JJ; Kim TJ; Kim WY; Lee JW; Lee SJ; Lee JH; Bae DS; Kim BG
Cancer Lett; 2007 Sep; 255(1):26-33. PubMed ID: 17467893
[TBL] [Abstract][Full Text] [Related]
37. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study.
Schmiemann V; Böcking A; Kazimirek M; Onofre AS; Gabbert HE; Kappes R; Gerharz CD; Grote HJ
Clin Cancer Res; 2005 Nov; 11(21):7728-34. PubMed ID: 16278393
[TBL] [Abstract][Full Text] [Related]
38. Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status.
Yanagawa N; Tamura G; Oizumi H; Endoh M; Sadahiro M; Motoyama T
Anticancer Res; 2011 Apr; 31(4):1211-4. PubMed ID: 21508367
[TBL] [Abstract][Full Text] [Related]
39. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer.
Liu Z; Zhao J; Chen XF; Li W; Liu R; Lei Z; Liu X; Peng X; Xu K; Chen J; Liu H; Zhou QH; Zhang HT
Lung Cancer; 2008 Oct; 62(1):15-22. PubMed ID: 18358560
[TBL] [Abstract][Full Text] [Related]
40. Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors.
Chang Q; Pang JC; Li KK; Poon WS; Zhou L; Ng HK
Hum Pathol; 2005 Dec; 36(12):1265-72. PubMed ID: 16311119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
